Australia markets open in 3 hours 46 minutes

Antisense Therapeutics Limited (ANP.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0970-0.0080 (-7.62%)
At close: 03:54PM AEST
Full screen
Previous close0.1050
Open0.1050
Bid0.0970 x 50000000
Ask0.1000 x 34112000
Day's range0.0960 - 0.1050
52-week range0.0730 - 0.3500
Volume424,086
Avg. volume610,097
Market cap70.223M
Beta (5Y monthly)1.26
PE ratio (TTM)N/A
EPS (TTM)-0.0150
Earnings date23 Aug 2022 - 29 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.42
  • Simply Wall St.

    We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • GlobeNewswire

    New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2

    Figure 1 Quad RNA ddPCR (Pooled) Figure 2 Quad RNA ddPCR (Female) LGMDR2, also referred to as dysferlinopathy, is a rare genetic muscle disease caused by mutations in the dysferlin gene (DYSF)Animal study conducted at MCRI in collaboration with Jain Foundation in the USStudy results showed significant decreases in target CD49d RNA and key immune cell RNA levels in the muscleData supports progression into a longer-term efficacy study planned for 3Q/4Q2022 Mark Diamond, Antisense Therapeutics Mana

  • GlobeNewswire

    Antisense Therapeutics to present poster at world’s largest NMD conference

    New York, NY, March 09, 2022 (GLOBE NEWSWIRE) -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference later this week. Dr. George Tachas, the Company’s Director of Drug Discovery and Patents, will present an e-poster on new data from its Phase II study of ATL1102 in patients with Duchenne muscular dystrophy (DMD). DMD is a rare genetic disorder th